EASL Highlights from the Hannover Liver Team 2026

You can now see the webbinar EASL Highlights from the Hannover Liver Team 2026 here. Summarizing the most important topics from EASL 2026.

This webinar from the liver team at Hannover Medical School summarizes the key clinical news from the EASL 2026 liver congress. In the field of viral hepatitis, promising phase 3 data for bepirovirsen was presented, making a functional cure for hepatitis B a realistic possibility for the first time. For hepatitis D and E, new promising antiviral substances were discussed, as well as the driving role of these viruses in acute-on-chronic liver failure (ACLF). Regarding liver cirrhosis and portal hypertension, new studies showed that an under-dilated TIPS stent reduces complications, and that a halved albumin dose is both safer and equally effective in acute kidney injury. Finally, lifestyle interventions were emphasized as the most important cornerstone in fatty liver disease (MASLD), while groundbreaking phase 2 data for senolytic drugs demonstrated an exceptional reduction in liver fibrosis.

(this summary is AI generated and not proofread)

Speakers from the Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology at Hannover Medical School (MHH), Germany:

Thanks to our sponsor

Keywords:

EASL 2026

Hepatitis B and D (Bepirovirsen, Bulevirtide)

Liver Cirrhosis and ACLF (TIPS, Albumin)

MASLD (Fatty Liver Disease, Senolytics)

Cholestatic Liver Diseases (PBC, PSC)